TYK Medicines, Inc (HKG:2410)
32.55
-2.55 (-7.26%)
Apr 3, 2025, 4:08 PM HKT
TYK Medicines Statistics
Total Valuation
TYK Medicines has a market cap or net worth of HKD 12.07 billion. The enterprise value is 11.77 billion.
Market Cap | 12.07B |
Enterprise Value | 11.77B |
Important Dates
The last earnings date was Thursday, March 27, 2025.
Earnings Date | Mar 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TYK Medicines has 370.84 million shares outstanding. The number of shares has increased by 16.52% in one year.
Current Share Class | n/a |
Shares Outstanding | 370.84M |
Shares Change (YoY) | +16.52% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 2.22% |
Owned by Institutions (%) | 18.72% |
Float | 214.06M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 27.89 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -28.59 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.37.
Current Ratio | 1.97 |
Quick Ratio | 1.59 |
Debt / Equity | 0.37 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -27.34 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -28.86% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -54.86% |
Revenue Per Employee | 744 |
Profits Per Employee | -2.69M |
Employee Count | n/a |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 28.24 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 53.20 |
Average Volume (20 Days) | 2,399,450 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TYK Medicines had revenue of HKD 113,866 and -411.79 million in losses.
Revenue | 113,866 |
Gross Profit | 14,898 |
Operating Income | -365.82M |
Pretax Income | -412.82M |
Net Income | -411.79M |
EBITDA | -351.50M |
EBIT | -365.82M |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 490.01 million in cash and 188.20 million in debt, giving a net cash position of 301.82 million or 0.81 per share.
Cash & Cash Equivalents | 490.01M |
Total Debt | 188.20M |
Net Cash | 301.82M |
Net Cash Per Share | 0.81 |
Equity (Book Value) | 502.89M |
Book Value Per Share | n/a |
Working Capital | 297.86M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 13.08% |
Operating Margin | -321,276.00% |
Pretax Margin | -362,550.92% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TYK Medicines does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -16.52% |
Shareholder Yield | -16.52% |
Earnings Yield | -3.41% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |